Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
5-HT2 ANTAGONISM AND EPS BENEFITS - IS THERE A CAUSAL CONNECTION
Autore:
KAPUR S;
Indirizzi:
CLARKE INST PSYCHIAT,PET CTR,250 COLL ST TORONTO ON M5T 1R8 CANADA
Titolo Testata:
Psychopharmacology
fascicolo: 1-2, volume: 124, anno: 1996,
pagine: 35 - 39
Fonte:
ISI
Lingua:
ENG
Soggetto:
HALOPERIDOL-INDUCED CATALEPSY; NEUROLEPTIC-INDUCED PARKINSONISM; D2-DOPAMINE RECEPTOR OCCUPANCY; SCHIZOPHRENIC-PATIENTS; RITANSERIN; CLOZAPINE; PLACEBO; DRUGS; RISPERIDONE; MECHANISM;
Keywords:
SCHIZOPHRENIA; RECEPTORS; SEROTONIN; DOPAMINE; PARKINSONISM; EXTRAPYRAMIDAL SYMPTOMS; PET;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
50
Recensione:
Indirizzi per estratti:
Citazione:
S. Kapur, "5-HT2 ANTAGONISM AND EPS BENEFITS - IS THERE A CAUSAL CONNECTION", Psychopharmacology, 124(1-2), 1996, pp. 35-39

Abstract

This article examines the hypothesis that 5-HT2 antagonism ameliorates extrapyramidal side effects (EPS) induced by the blockade of D-2 dopamine receptors by antipsychotics. Neuroanatomical and neurophysiological data confirm the existence of pathways whereby 5-HT2 antagonism may influence EPS. The experimental data in rodents is marginally positive, but shows that the net effect of 5-HT2 antagonism is dependent upon the precise conditions under which catalepsy is induced. The data inmonkeys are mainly negative. Studies in patients who have received adjunct 5-HT2 antagonists in addition to typical neuroleptics lend some support the the hypothesis, but are not conclusive. It is reasoned that 5-HT2 antagonism plays no role in clozapine's freedom from EPS, but it may be responsible for risperidone's decreased propensity to cause EPS. The article concludes that there is support for a conditional role of 5-HT2 in decreasing EPS: 5-HT2 antagonists may delay the onset and decrease the severity of EPS but cannot totally eliminate its occurrence. The implications of these findings for the next generation of combined 5-HT2/D-2 antagonists are discussed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:28:26